Alora Pharmaceuticals Wins Top Pharmaceutical Award – Best of the Best in Healthcare Marketing Honored at Event in NYC on September 23rd

September 30, 2022

PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72… Learn More

Shannon Faught Named 2022 Women of Influence by the Atlanta Business Chronicle

September 14, 2022

Alora Pharmaceuticals, LLC a specialty pharmaceutical company based in Alpharetta, GA is pleased to announce that Shannon Faught, Chief Commercial Officer for Alora’s branded pharmaceutical business has been recognized as a 2022 Women of Influence by the Atlanta Business Chronicle. The Atlanta Business Chronicle has selected 21 Atlanta area women who are driving business and… Learn More

Alora Pharmaceuticals adds Chief Quality Officer to its Senior Leadership Team

July 7, 2022

Pharmaceutical Executive Miguel Gomez will lead Alora Pharmaceutical Global Quality strategies Alora Pharmaceuticals, announced today that Miguel Gomez, has been appointed Chief Quality Officer. With his appointment, Alora Pharmaceuticals, LLC marks the establishment of a global quality and compliance-focused organization across the entire pharmaceutical business. Mr. Gomez is a veteran executive in the pharmaceutical industry… Learn More

EY Announces Art Deas, of Alora Pharmaceuticals as an Entrepreneur Of The Year® 2022 Southeast Award Finalist

June 23, 2022

Celebrating ambitious pioneers tackling our biggest challenges Ernst & Young LLP (EY US) has announced that Harold “Art” Deas, of Alora Pharmaceuticals was named an Entrepreneur Of The Year® 2022 Southeast Award finalist. Entrepreneur Of The Year is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big… Learn More

Alora Pharmaceuticals Strengthens Leadership Team with Experienced Chief Commercial Officer

June 20, 2022

Pharmaceutical Executive Shannon Faught will lead Alora Pharmaceutical commercial strategies Alora Pharmaceuticals, announced today that Shannon Faught has been appointed Chief Commercial Officer. In this role, Ms. Faught will lead the growth of the Branded Pharmaceutical business of Alora Pharmaceuticals, LLC. Ms. Faught is a veteran commercial executive in the pharmaceutical industry with extensive sales,… Learn More

Avion Pharmaceuticals, LLC and Acella Pharmaceuticals, LLC Top MedReps Best Places to Work in Medical Sales

December 2, 2021

Alora Pharmaceuticals’ Subsidiaries Awarded Top Small Employer for Fourth Consecutive Year Alora Pharmaceuticals today announced its subsidiaries Avion Pharmaceuticals, LLC and Acella Pharmaceuticals, LLC earned the top spot for small companies in MedReps Best Places to Work in Medical Sales 2022 survey, marking the fourth consecutive year of being honored. Surveying more than 2,300 professionals,… Learn More

Avion Pharmaceuticals, LLC, and Acella Pharmaceuticals, LLC, awarded 2nd consecutive ‘Best Place to Work in Medical Sales*’ recognition

December 3, 2020

Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, and affiliate company Acella Pharmaceuticals, LLC, have earned back-to-back annual recognition as the “Best Place to Work in Medical Sales: Small Pharma Category.” This announcement was made by MedReps, the leading job site for experienced industry professionals. In addition, for the first time, Avion and Acella also were… Learn More

Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® (Thyroid Tablets, USP) Due to Super Potency

May 21, 2020

Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent. The product may have up to 115.0% of the labeled amount of Liothyronine (T3). Risk… Learn More

Important Information About COVID-19

March 17, 2020

As a valued member of the Acella Pharmaceuticals’ community, nothing is more important to us than your health and safety. As the spread of coronavirus, known as COVID-19, continues to be a growing concern across the country, we wanted to provide you with important information about the availability of our products. In anticipation of the… Learn More

Alora Pharmaceuticals, LLC, Announces Corporate Office Expansion

May 29, 2018

Alora Pharmaceuticals, LLC, parent company of Avion Pharmaceuticals, LLC, and Acella Pharmaceuticals, LLC, announced the relocation of the corporate headquarters of its two companies to a new 58,000 sq. ft. facility at 1880 McFarland Parkway in Alpharetta, Georgia. Both companies completed the move in late February. The new headquarters will provide increased office space, climate-controlled… Learn More

Acella Pharmaceuticals Signs Product Development Agreement with Catalent To Bring Opioid-Abuse Deter

August 10, 2017

Acella Pharmaceuticals, LLC, a leading U.S. manufacturer of specialty pharmaceuticals across several therapeutic categories, today announced an exclusive, multi-year, multi-product development and licensing partnership with Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, to develop, manufacture, and commercialize a new portfolio of… Learn More

Acella Pharmaceuticals, LLC, Announces Approval of Generic to Vituz® Oral Solution

July 27, 2017

Acella Pharmaceuticals, LLC, a leading U.S. developer of specialty pharmaceuticals across several therapeutic categories, recently announced the Food and Drug Administration’s approval of the Company’s abbreviated new drug application (ANDA) for a Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution 5 mg/4 mg per 5 mL as a bioequivalent product to VITUZ® Oral Solution. This approval… Learn More

Acella Pharmaceuticals, LLC, Announces Approval of a Generic Bromfed Antihistamine/Decongestant

October 28, 2016

Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, recently secured approval for a sugar-free bioequivalent to the antihistamine/decongestant Bromfed DM® Cough Syrup (brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup, 2mg/30mg/10mg per 5mL).* This combination of pharmaceutical ingredients is used to temporarily relieve the symptoms caused by the common cold, flu, allergies, and other breathing illnesses…. Learn More